RIP
IRD

Reliant Investment Partners’s Opus Genetics IRD Stock Holding History

Reliant Investment Partners’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$45.5K – 131
2026
Q1 		$45.5K Hold
10,000
– – 0.04% 112
2025
Q4 		$20.1K Hold
10,000
– – 0.02% 109
2025
Q3 		$18.8K Hold
10,000
– – 0.01% 107
2025
Q2 		$9.42K Hold
10,000
– – 0.01% 110
2025
Q1 		$9.82K Hold
10,000
– – 0.01% 95
2024
Q4 		$11.9K Buy
+10,000
New +$11.5K 0.01% 110

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Reliant Investment Partners's IRD Position: Q2 2026 in Review

Reliant Investment Partners sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 10,000 shares — an estimated $45.5K sold.

Reliant Investment Partners first reported a position in IRD in Q4 2024 and held it in 6 quarters. The position peaked at $45.5K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Reliant Investment Partners reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
  • Reliant Investment Partners sold 10,000 Opus Genetics shares in Q2 2026, an estimated $45.5K.
  • Reliant Investment Partners first reported a position in Opus Genetics in Q4 2024 and held it in 6 quarters.
  • Reliant Investment Partners's Opus Genetics position peaked at $45.5K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Reliant Investment Partners's 13F filing for Q2 2026, filed 11 Aug 2026.